KIMS corrects investor presentation for Q2 FY26, clarifies no financial impact, reports mixed results
KIMS corrected its Q2 FY26 investor presentation for a bed count error, confirming no financial impact. The company reported ₹964.9 crore revenue (up 23.3% YoY) but ₹208.2 crore EBITDA (down 6.7% YoY) and ₹72 crore PAT (down 40.3% YoY).
While the data correction itself has no financial impact, the Q2 FY26 financial results, particularly the year-on-year decline in profitability (EBITDA and PAT), are material to investors and could influence market perception, warranting a medium impact level.
The announcement includes a correction to a data error in the investor presentation, which the company states has no financial impact. However, the Q2 FY26 results present a mixed picture with strong year-on-year revenue growth offset by a significant decline in EBITDA and PAT, leading to an overall neutral sentiment.
Krishna Institute of Medical Sciences Limited (KIMS) has issued a corrigendum to its Investor Presentation, correcting an inadvertent error regarding the number of beds. The original presentation was uploaded on November 7, 2025, and the corrected version was uploaded on November 11, 2025. The corrections primarily involve updated occupancy percentages and adjustments to operational, census, non-census, and occupancy percentages on pages 18, 19, and 22. A final comment under the Bengaluru section on page 25 was also revised. The company clarified that these data corrections have no impact on its financial statements or performance. The Investor Presentation also provided the consolidated financial and operational highlights for Q2 FY26: * Total Revenue: ₹9,649 million (₹964.9 crore), a growth of 23.3% year-on-year and 9.8% quarter-on-quarter. * EBITDA: ₹2,082 million (₹208.2 crore), a decline of 6.7% year-on-year but a growth of 4.3% quarter-on-quarter. The EBITDA Margin stood at 21.6%. * Profit After Tax (PAT): ₹720 million (₹72 crore), a decline of 40.3% year-on-year and 15.3% quarter-on-quarter. * Consolidated Earnings Per Share (EPS): ₹1.67, a decline of 37.7% year-on-year and 14.7% quarter-on-quarter. * Operational highlights include a 15.3% year-on-year increase in IP Volume to 64,288 and a 25.1% year-on-year increase in OP Volume to 592,725. * Average Revenue Per Occupied Bed (ARPOB) grew by 9.8% year-on-year to ₹42,016, and Average Revenue Per Patient (ARPP) grew by 7.3% year-on-year to ₹150,624. * The company highlighted its expansion plans, including: Bengaluru (Project-2) with 361 beds and Ongole with 50 incremental beds expected by Q3 FY26; Anantapur with 250 incremental beds by Q4 FY26; Kondapur with 550 incremental beds by Q1 FY27; and a new Rajahmundry unit with 350 beds by Q4 FY27.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.